TScan Therapeutics (TCRX) Assets Average (2021 - 2026)

TScan Therapeutics (TCRX) has 6 years of Assets Average data on file, last reported at $215.4 million in Q1 2026.

• On a quarterly basis, Assets Average fell 38.79% year-over-year to $215.4 million in Q1 2026; TTM through Mar 2026 was $215.4 million, a 38.79% decrease from a year earlier, with the FY2025 full-year figure at $300.0 million, down 6.74% from the prior year.
• Assets Average for Q1 2026 stood at $215.4 million, down from $245.5 million in the prior quarter.
• Over the last five years, Assets Average for TCRX reached as high as $361.4 million in Q3 2024 and fell as low as $158.9 million in Q3 2022.
• Historically, Assets Average has averaged $258.3 million across 5 years, with a median of $256.5 million in 2024.
• Across the five-year window, Assets Average surged 91.37% in 2023 and sank 38.79% in 2026, its largest moves.
• Year by year, Assets Average stood at $182.3 million in 2022, then soared by 54.58% to $281.8 million in 2023, then rose by 27.61% to $359.6 million in 2024, then plunged by 31.72% to $245.5 million in 2025, then slipped by 12.27% to $215.4 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $215.4 million in Q1 2026, $245.5 million in Q4 2025, and $280.4 million in Q3 2025.